Aeglea Biotherapeutics Inc. (AGLE) Trading Down 2.6%
Shares of Aeglea Biotherapeutics Inc. (NASDAQ:AGLE) fell 2.6% during mid-day trading on Thursday . The stock traded as low as $7.64 and last traded at $7.90, with a volume of 58,041 shares. The stock had previously closed at $8.11.
Separately, Zacks Investment Research upgraded Aeglea Biotherapeutics from a “sell” rating to a “hold” rating in a report on Tuesday.
The stock has a 50-day moving average of $5.64 and a 200 day moving average of $6.55. The stock’s market capitalization is $104.07 million.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/15/aeglea-biotherapeutics-inc-agle-trading-down-2-6.html
Aeglea Biotherapeutics (NASDAQ:AGLE) last posted its quarterly earnings data on Tuesday, August 9th. The company reported ($0.46) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.43) by $0.03. On average, equities analysts anticipate that Aeglea Biotherapeutics Inc. will post ($4.77) EPS for the current year.
Several large investors have recently bought and sold shares of the stock. Ghost Tree Capital LLC purchased a new stake in Aeglea Biotherapeutics during the second quarter valued at about $243,000. Perceptive Advisors LLC purchased a new stake in Aeglea Biotherapeutics during the second quarter valued at about $515,000. Finally, VHCP Management II LLC purchased a new stake in Aeglea Biotherapeutics during the second quarter valued at about $1,527,000. Hedge funds and other institutional investors own 40.71% of the company’s stock.
About Aeglea Biotherapeutics
Aeglea BioTherapeutics, Inc is a biotechnology company. The Company is engaged in the development of enzyme-based therapeutics in the field of amino acid metabolism to treat inborn errors of metabolism (IEM) and cancer. Its engineered human enzymes are designed to degrade specific amino acids in the blood.
Receive News & Ratings for Aeglea Biotherapeutics Inc. Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Aeglea Biotherapeutics Inc. and related companies with MarketBeat.com’s FREE daily email newsletter.